Diplo TRT: What Clinicians Should Tell Patients

Why Diplo's Public TRT Disclosure Matters Clinically

Diplo discussed his testosterone replacement therapy use on a podcast, making him one of the more prominent public figures to normalize the conversation around male hormone optimization. That candor is clinically relevant. Patients who hear a high-profile figure describe fatigue relief, improved body composition, or better mood on TRT arrive at telehealth and in-person visits with specific questions, sometimes with pre-formed expectations that clinicians need to address carefully and without dismissing the underlying concern.

What Diplo Actually Said

Diplo stated on a podcast that he uses TRT, describing it in the context of energy and performance. He did not publicly specify a formulation, dose, or prescribing physician. Clinicians should note this distinction: a celebrity endorsing a therapy category is not the same as endorsing a specific protocol, and patients sometimes conflate the two.

The "Celebrity Effect" on TRT Demand

Google Trends data show consistent search-volume spikes for "TRT" following high-profile media appearances by athletes, musicians, or podcasters discussing the therapy. This pattern mirrors what researchers have documented with other treatments. A 2021 analysis in the Journal of Sexual Medicine found that direct-to-consumer advertising and media coverage independently predicted men seeking low-testosterone evaluations, regardless of whether they met diagnostic criteria [1].

Clinicians should use these patient-initiated conversations as teaching moments, not gatekeeping moments. A man who shows up asking about "what Diplo takes" may well have undiagnosed hypogonadism.

Who Actually Qualifies for TRT: The Diagnostic Standard

TRT is not appropriate for every man who feels tired or notices reduced muscle mass. The American Urological Association (AUA) and the Endocrine Society both require biochemical confirmation of low testosterone combined with consistent clinical symptoms before initiating therapy.

The Two-Draw Rule

The Endocrine Society's 2018 Clinical Practice Guideline on Male Hypogonadism specifies that diagnosis requires two separate morning fasting total testosterone measurements below 300 ng/dL, drawn on different days [2]. A single low reading is insufficient. Labs drawn in the afternoon can be 20 to 30% lower than morning values due to diurnal variation, which means a 3 p.m. Draw at 280 ng/dL may not reflect true hypogonadism.

Symptom Criteria

The Endocrine Society guideline lists the following as the most specific symptoms: decreased spontaneous erections, loss of body or facial hair, gynecomastia, very small or shrinking testes, and unexplained infertility [2]. Less specific symptoms including fatigue, low libido, and depressed mood are common but require exclusion of other causes before attributing them to hypogonadism.

Lab Panel at Baseline

Before prescribing, clinicians should obtain:

• Total testosterone (two morning draws)
• Free testosterone (calculated or equilibrium dialysis)
• LH and FSH (to distinguish primary from secondary hypogonadism)
• PSA
• Hematocrit and complete blood count
• Estradiol
• Prolactin if secondary hypogonadism suspected

This panel is consistent with AUA guidance on evaluation and management of testosterone deficiency [3].

Formulations: Injectables, Gels, and Newer Options

Clinicians prescribing TRT have a wider menu of formulations than existed even a decade ago. Each carries a distinct pharmacokinetic profile, adherence profile, and risk pattern.

Injectable Testosterone

Testosterone cypionate and testosterone enanthate remain the most widely used formulations in the United States. Typical dosing is 100 to 200 mg intramuscularly every 1 to 2 weeks, though many clinicians split weekly doses to reduce peak-to-trough variation. Subcutaneous injection at lower volumes (50 to 100 mg weekly) has gained traction as an off-label approach that reduces hematocrit risk and injection-site discomfort.

The peak-to-trough swings with biweekly intramuscular injections are clinically meaningful. A 2020 study in Andrology documented that men on biweekly IM injections experienced supraphysiologic testosterone levels in the first 48 to 72 hours post-injection, sometimes exceeding 1,200 ng/dL, before falling near hypogonadal levels by day 13 to 14 [4]. This fluctuation correlates with mood instability and erythrocytosis risk.

Topical Gels and Transdermal Patches

Testosterone gel (1% and 1.62%, brand names AndroGel, Testim) delivers more stable serum levels but requires strict transfer precautions. The FDA added a black-box warning in 2009 regarding secondary exposure risk to women and children through skin contact [5]. Patches (Androderm) offer similar stability but have higher rates of application-site reactions.

Newer Delivery Systems

Testosterone undecanoate (Aveed, injectable) requires in-office administration every 10 weeks after a loading phase, with a 30-minute post-injection observation period due to pulmonary oil microembolism risk. Oral testosterone undecanoate (Jatenzo, Tlando) received FDA approval in 2019 and 2022 respectively, offering an alternative for patients who cannot or will not self-inject [6].

Testosterone nasal gel (Natesto) avoids skin transfer risk and preserves intratesticular testosterone more than other routes, making it a consideration for men who have not yet completed their families.

The TRAVERSE Trial: What the Cardiovascular Data Actually Show

For years, conflicting observational data left clinicians uncertain about TRT and cardiovascular risk. The TRAVERSE trial resolved a significant portion of that uncertainty.

Trial Design and Primary Results

TRAVERSE enrolled 5,246 men aged 45 to 80 with hypogonadism (total testosterone <300 ng/dL) and either pre-existing cardiovascular disease or elevated cardiovascular risk. Participants were randomized to testosterone gel 1.62% or placebo and followed for a mean of 22 months. The primary endpoint was major adverse cardiovascular events (MACE): non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death.

Published in the New England Journal of Medicine in 2023, TRAVERSE found that TRT was non-inferior to placebo for MACE (7.0% vs. 7.3%; hazard ratio 0.96; 95% CI 0.78 to 1.17) [7]. This was a landmark finding: TRT did not increase heart attack or stroke risk in a properly diagnosed, symptomatic population over roughly two years.

Signals That Still Require Monitoring

TRAVERSE did identify higher rates of atrial fibrillation (3.5% vs. 2.4%), pulmonary embolism (0.9% vs. 0.5%), and acute kidney injury in the testosterone group [7]. These signals did not reach the threshold to overturn the primary non-inferiority finding, but they are clinically actionable. Patients with pre-existing atrial fibrillation or thromboembolic history warrant extra caution and shared decision-making.

As the Endocrine Society stated in their 2023 commentary on TRAVERSE: "The trial provides reassurance that testosterone therapy does not increase the risk of major adverse cardiovascular events in men with hypogonadism who have or are at risk for cardiovascular disease, but clinicians should remain attentive to the observed risks of atrial fibrillation and pulmonary embolism" [8].

Polycythemia: The Most Common Serious Adverse Effect

Erythrocytosis (hematocrit above 54%) is the most frequently encountered serious adverse effect of TRT, particularly with injectable formulations. Testosterone stimulates erythropoietin production and directly increases red cell mass.

Incidence Figures

A 2019 meta-analysis in the Journal of Clinical Endocrinology and Metabolism that pooled data from 35 randomized controlled trials found erythrocytosis rates of approximately 5.7% in TRT-treated men versus 0.8% in placebo groups [9]. Injectable formulations carried higher risk than gels, consistent with their higher peak testosterone levels.

Clinical Management

The AUA guideline recommends checking hematocrit at 3 months and 6 months after initiation, then annually [3]. If hematocrit exceeds 54%, clinicians should:

1. Hold TRT temporarily
2. Evaluate for secondary causes (sleep apnea is common and exacerbates erythrocytosis)
3. Consider dose reduction or formulation switch
4. Consider therapeutic phlebotomy in symptomatic or persistently elevated cases

Switching from biweekly intramuscular injections to weekly subcutaneous dosing often reduces erythrocytosis without requiring full discontinuation.

Fertility, Testicular Suppression, and the HCG Question

TRT suppresses the hypothalamic-pituitary-gonadal (HPG) axis. Exogenous testosterone signals the pituitary to reduce LH and FSH secretion, which drops intratesticular testosterone and halts spermatogenesis. This effect begins within weeks of starting therapy.

Fertility Counseling Before Starting

Any man who has not yet completed his family should be counseled on fertility preservation before initiating TRT. The American Society for Reproductive Medicine (ASRM) practice committee recommends sperm banking as a first step for men with reproductive intent [10].

Human Chorionic Gonadotropin as an Alternative

Human chorionic gonadotropin (hCG) mimics LH and can maintain intratesticular testosterone and spermatogenesis in men with secondary hypogonadism. Some clinicians co-administer hCG (typically 500 to 1,000 IU subcutaneously two to three times weekly) with TRT to preserve testicular volume and fertility potential, though this approach remains off-label and evidence is largely observational.

A 2013 study in The Journal of Urology found that hCG co-administration maintained intratesticular testosterone levels and semen parameters in hypogonadal men on exogenous testosterone [11]. Clinicians who manage younger patients on TRT should be aware of this option.

Monitoring Schedule: A Practical Framework for Clinicians

The following schedule reflects the synthesis of Endocrine Society, AUA, and American Association of Clinical Endocrinologists (AACE) guidance for monitoring patients on TRT.

Months 1 to 3

• Recheck total and free testosterone 3 to 4 weeks after starting injectable therapy (draw mid-cycle for injectables), or after 4 weeks for topical formulations.
• Target: total testosterone in the mid-normal range, 400 to 700 ng/dL.
• Recheck hematocrit and PSA.
• Assess symptom response using a validated tool such as the Androgen Deficiency in Aging Males (ADAM) questionnaire [12].

Months 3 to 6

• Repeat full lab panel: total T, free T, estradiol, hematocrit, PSA, LH/FSH if relevant.
• If estradiol is above 40 to 50 pg/mL with symptoms of excess (gynecomastia, water retention, mood changes), consider aromatase inhibitor use, though this is off-label and controversial.
• Review injection technique or gel adherence.

Annual Monitoring

• Digital rectal exam and PSA annually for men 40 and older, consistent with AUA prostate cancer early detection guidelines [3].
• Bone mineral density at baseline and every 1 to 2 years if osteoporosis is a concern.
• Fasting lipids annually, as TRT can modestly reduce HDL with some formulations.

PSA, Prostate, and the Question Patients Always Ask

Patients who have read about TRT online frequently ask whether it causes prostate cancer. The honest clinical answer is nuanced.

What the Evidence Shows

TRT does not appear to initiate de novo prostate cancer. The "saturation model," proposed by Morgentaler and Traish in a 2009 paper in the European Urology, holds that androgen receptors in prostate tissue become saturated at relatively low testosterone concentrations, meaning supraphysiologic levels do not proportionally increase cancer risk [13]. This model has gained wide acceptance and influenced guideline shifts.

TRT can stimulate growth of pre-existing, undetected prostate cancer. PSA monitoring is not optional. A PSA rise of more than 1.4 ng/mL above baseline within any 12-month period, or an absolute PSA above 4 ng/mL, warrants urology referral before continuing therapy.

Active Surveillance and TRT

Men on active surveillance for low-risk prostate cancer historically were excluded from TRT. More recent evidence, including a 2020 series published in European Urology, suggests carefully selected men on active surveillance may receive TRT without accelerating disease progression, provided close oncologic follow-up is maintained [14]. This is a shared decision-making conversation requiring urologic input.

Sleep Apnea: The Often-Missed Contraindication

Obstructive sleep apnea (OSA) is a relative contraindication to TRT that clinicians frequently underscreen. TRT worsens OSA by increasing upper airway soft tissue volume and altering ventilatory drive.

A randomized trial published in JAMA Internal Medicine in 2012 found that testosterone administration significantly worsened hypoxemia during sleep in men with pre-existing sleep apnea compared to placebo [15]. Before initiating TRT in any patient who reports snoring, daytime sleepiness, or whose bed partner reports apneic episodes, clinicians should obtain a sleep study or at minimum use a validated screening tool such as the STOP-BANG questionnaire.

Men already treated with CPAP and well-controlled OSA can generally receive TRT with continued monitoring.

What to Tell the Patient Who Mentions Diplo

Patients who arrive citing Diplo or another celebrity as their reason for interest in TRT deserve a structured, non-dismissive response. Here is a practical conversation framework.

First, acknowledge the patient's interest without validating or invalidating the celebrity's choice. Diplo's experience is real to him. Whether he was properly diagnosed and monitored is unknown from public information.

Second, explain that candidacy requires labs. A feeling of low energy or reduced performance is not sufficient. Two morning testosterone draws on separate days are the starting point.

Third, if labs confirm hypogonadism, explain that effective, guideline-supported therapy exists and that the risks are manageable with proper monitoring.

Fourth, if labs are normal, discuss other causes of the patient's symptoms: sleep quality, thyroid function, depression, metabolic syndrome, and anemia all produce fatigue and reduced libido.

The Endocrine Society Clinical Practice Guideline is explicit: "We recommend against making a diagnosis of androgen deficiency in men with nonspecific symptoms in the absence of consistently low serum testosterone concentrations" [2].

Common Patient Misconceptions About TRT

"TRT Will Make Me Bigger and Stronger Immediately"

Physiologic dose TRT in properly diagnosed hypogonadal men restores testosterone to the normal range. It is not anabolic steroid therapy. Body composition improvements, when they occur, develop over 3 to 6 months and are modest in most patients: a 2016 systematic review in PLOS ONE found an average lean mass increase of 1.6 kg and fat mass decrease of 2.0 kg over 12 months of TRT in hypogonadal men [16].

"TRT Is Forever"

TRT can be discontinued. Endogenous testosterone production may recover, particularly in men with secondary hypogonadism, though recovery timelines vary widely. Men who started TRT before age 40 for secondary hypogonadism may be candidates for a trial off therapy with monitoring.

"Natural Boosters Work Just as Well"

No dietary supplement has demonstrated in a randomized controlled trial that it raises total testosterone to clinically meaningful levels in men with confirmed hypogonadism. A 2020 review in Translational Andrology and Urology found that zinc supplementation may modestly raise testosterone in men who are zinc-deficient, but the effect size is far below what TRT achieves [17].